We hope that our findings can contribute to available knowledge, report the expression of GLUT1–4 in breast cancer, and more importantly, provide a reference for the potential individualized metabolic inhibition therapy of TNBC using hGLUT1 inhibitors. The gene discussed is SLC2A1; the disease is breast carcinoma.